Researcher Profile

Researcher Profile

Harold Harvey, MD

Harold Harvey, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Breast Cancer
Sarcoma Cancer

Research Interests

  • Breast Neoplasms
  • Therapeutics
  • Neoplasms
  • Aminoglutethimide
  • Drug Therapy
  • Estrogens
  • Neoplasm Metastasis
  • Tamoxifen
  • Bone and Bones
  • Prostatic Neoplasms
  • Aromatase Inhibitors
  • Hydrocortisone

Clinical Trials

A Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: THE ABC Trial
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer
Predicting Breast Cancer Metastasis: Signaling Pathway Biomarker Identification Using Reverse Phase Protein Microarray (RPMA) Technology

Recent Publications


Cheng, Y, Ren, X, Yuan, Y, Shan, Y, Li, L, Chen, X, Zhang, L, Takahashi, Y, Yang, JW, Han, B, Liao, J, Li, Y, Harvey, H, Ryazanov, A, Robertson, GP, Wan, G, Liu, D, Chen, AF, Tao, Y & Yang, JM 2018, 'Correction to: eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis (Oncogene, (2016), 35, 49, (6293-6308), 10.1038/onc.2016.166)', Oncogene, vol. 37, no. 33, pp. 4633-4634.


Somlo, G, Frankel, PH, Arun, BK, Ma, CX, Garcia, AA, Cigler, T, Cream, L, Harvey, H, Sparano, JA, Nanda, R, Chew, HK, Moynihan, TJ, Vahdat, LT, Goetz, MP, Beumer, JH, Hurria, A, Mortimer, J, Piekarz, R, Sand, S, Herzog, J, Van Tongeren, LR, Ferry-Galow, KV, Chen, AP, Ruel, C, Newman, EM, Gandara, DR & Weitzel, JN 2017, 'Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083', Clinical Cancer Research, vol. 23, no. 15, pp. 4066-4076.
Jia, H, Truica, C, Wang, B, Wang, Y, Ren, X, Harvey, H, Song, J & Yang, J-M 2017, 'Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects', Drug Resistance Updates, vol. 32, pp. 1-15.
Yin, M, Wang, W, Drabick, J & Harvey, H 2017, 'Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: A comparative study', BMC Cancer, vol. 17, no. 1, 295.


Cheng, Y, Ren, X, Yuan, Y, Shan, Y, Li, L, Chen, X, Zhang, L, Takahashi, Y, Yang, JW, Han, B, Liao, JJ, Li, Y, Harvey, H, Ryazanov, A, Robertson, G, Wan, G, Liu, D, Chen, AF, Tao, Y & Yang, J-M 2016, 'EEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis', Oncogene, vol. 35, no. 49, pp. 6293-6308.
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, H, Kaag, MG, Van De Putte, EEF, Horenblas, S & Drabick, J 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715.
Yin, M, MacKley, HB, Drabick, JJ & Harvey, HA 2016, 'Primary female breast sarcoma: Clinicopathological features, treatment and prognosis', Scientific reports, vol. 6, 31497.


Al-Marrawi, MY, Cream, L, Mallon, CA, Holder, S, Joshi, M, Harvey, H, Talamo, G & Drabick, J 2015, 'Effect of topical vaginal androgens in a woman on the testosterone levels of her sexual partner with prostate cancer', Journal of Clinical Oncology, vol. 33, no. 5, pp. 521-522.
El-Deiry, WS, Vijayvergia, N, Xiu, J, Scicchitano, A, Lim, B, Yee, NS-S, Harvey, H, Gatalica, Z & Reddy, S 2015, 'Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites', Cancer Biology and Therapy, vol. 16, no. 12, pp. 1726-1737.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)